China's Duality Biotherapeutics shares set to rise 91% in Hong Kong debut
15/04/2025 02:20
SYDNEY, April 15 (Reuters) - Shares of China's Duality Biotherapeutics 9606.HK were set to rise 91.3% in their Hong Kong debut on Tuesday after the company raised $213 million in an initial public offering launched as financial markets reacted savagely to the U.S tariffs package. (Reporting by Scott Murdoch in Sydney and Donny Kwok in Hong Kong; Editing by Tom Hogue) ((Scott.Murdoch@thomsonreuters.com;))
Recent news on Duality Biotherapeutics
See all newsDuality Biotherapeutics rises most in near six weeks on Roche's Genentech tie-up
Brief: Duality Biotherapeutics Says Global Research And Development Collaboration And License Agreement With Genentech
Brief: Duality Biotherapeutics Obtains Acceptance From Shanghai Securities Regulatory Bureau For Counselling On Proposed RMB Share Listing
Brief: Duality Biotherapeutics Announces Share Repurchase Plan Of Up To $40 Million
Brief: Duality Biotherapeutics Approved Proposed RMB Share Issue On Sci-Tech Board